We investigated in vitro and in vivo combination effects of GPR119 agonists with TKIs in breast cancer and hepatoma cells, and clarified the mechanistic basis for the anticancer effects of GPR119 agonists, focusing on autophagy inhibition. The gene discussed is GPR119; the disease is breast carcinoma.